AI
CYTK icon

Atria Investments’s Cytokinetics CYTK Stock Holding History

Atria Investments’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
13,262
+282
+2% +$20.2K 0.01% 1045
2026
Q1 		$856K Sell
12,980
-1,390
-10% -$88.3K 0.01% 1145
2025
Q4 		$913K Buy
14,370
+2,223
+18% +$138K 0.01% 1118
2025
Q3 		$668K Buy
+12,147
New +$500K 0.01% 1258

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Atria Investments's CYTK Position: Q2 2026 in Review

Atria Investments increased its Cytokinetics (CYTK) stake by 2.2% in Q2 2026, buying an estimated $20.2K and bringing the position to 13,262 shares worth $1.13M. The position accounts for 0.01% of the portfolio, ranked #1045.

Atria Investments first reported a position in CYTK in Q3 2025 and has held it in 4 quarters since. 484 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Atria Investments held 13,262 shares of Cytokinetics worth $1.13M as of Q2 2026.
  • Atria Investments bought 282 Cytokinetics shares in Q2 2026, an estimated $20.2K.
  • Cytokinetics made up 0.01% of Atria Investments's portfolio in Q2 2026, its #1045 holding.
  • Atria Investments first reported a position in Cytokinetics in Q3 2025 and has held it in 4 quarters since.
  • 484 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.